Search

Your search keyword '"Anker, SD"' showing total 934 results

Search Constraints

Start Over You searched for: Author "Anker, SD" Remove constraint Author: "Anker, SD" Search Limiters Full Text Remove constraint Search Limiters: Full Text
934 results on '"Anker, SD"'

Search Results

1. Request for regulatory guidance for cancer cachexia intervention trials

2. A prospective comparison of alginate-hydrogel with standard medical therapy to determine impact on functional capacity and clinical outcomes in patients with advanced heart failure (AUGMENT-HF trial)

3. Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: Results from a phase 3 randomized, double-blind, placebo-controlled trial

5. Physical function endpoints in cancer cachexia clinical trials: Systematic Review 1 of the cachexia endpoints series.

6. Cardiac remodelling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology

7. Cardiac remodelling - Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology

8. Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM-AHF trial

9. Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology

10. International Exercise Recommendations in Older Adults (ICFSR): Expert Consensus Guidelines

11. Empagliflozin in heart failure with a preserved ejection fraction

12. COVID-19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology

14. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

15. Sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. The position paper of the Heart Failure Association of the European Society of Cardiology

16. Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP Heart Failure Long-Term Registry

18. Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial

19. Management of heart failure patients with COVID-19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology

20. Cardiovascular and renal outcomes with empagliflozin in heart failure

21. Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial

22. The impact of pharmacist/physician care on quality of life in elderly heart failure patients: results of the PHARM-CHF randomized controlled trial.

23. Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure

24. Heart Failure Association of the European Society of Cardiology position paper on frailty in patients with heart failure

25. Clinical evaluation of cardiovascular devices: principles, problems, and proposals for European regulatory reform: Report of a policy conference of the European Society of Cardiology†

26. Pharmacy-based interdisciplinary intervention for patients with chronic heart failure: results of the PHARM-CHF randomized controlled trial

27. Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

28. Roadmap for cardiovascular education across the European Society of Cardiology: inspiring better knowledge and skills, now and for the future

29. Physicians' guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry

30. Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry

31. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with RAAS-inhibitors - Coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology

32. Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Failure

33. PHARMacy-based interdisciplinary program for patients with Chronic Heart Failure (PHARM-CHF): rationale and design of a randomized controlled trial, and results of the pilot study.

34. The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure: BIOSTAT-CHF Subanalysis

35. Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry

37. New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment

38. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

39. Biomarkers in kidney and heart disease

40. Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction

42. ESC Guidelines on diabetes, pre- diabetes, and cardiovascular diseases developed in collaboration with the EASD - Summary

43. Atrial fibrillation impairs the diagnostic performance of cardiac natriuretic peptides in dyspneic patients. results from the BACH Study (Biomarkers in ACute Heart Failure)

44. Why cachexia kills: Examining the causality of poor outcomes in wasting conditions

45. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry

46. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012

47. AND ANTI-ENDOTOXIN CORE ANTIBODY LEVELS IN NON-OEDEMATOUS SEVERE CHRONIC HEART FAILURE

48. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery The Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA)

49. New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes

Catalog

Books, media, physical & digital resources